Association of metabolic dysfunction with cognitive decline and Alzheimer's disease: A review of metabolomic evidence

被引:11
作者
Amidfar, Meysam [1 ]
Askari, Gholamreza [1 ,2 ]
Kim, Yong-Ku [3 ]
机构
[1] Isfahan Univ Med Sci, Food Secur Res Ctr, Esfahan, Iran
[2] Isfahan Univ Med Sci, Dept Community Nutr, Sch Nutr & Food Sci, Esfahan, Iran
[3] Korea Univ, Coll Med, Dept Psychiat, Seoul, South Korea
关键词
Alzheimer's disease; Mild cognitive impairment; Metabolic disorders; Cognitive decline; Metabolomics; GLUCOSE-METABOLISM; AMYLOID-BETA; CEREBROSPINAL-FLUID; APOLIPOPROTEIN-E; MEDITERRANEAN DIET; INSULIN-RESISTANCE; TYPE-4; ALLELE; AMINO-ACIDS; FATTY-ACIDS; RISK-FACTOR;
D O I
10.1016/j.pnpbp.2023.110848
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The discovery of new biomarkers that can distinguish Alzheimer's disease (AD) from mild cognitive impairment (MCI) in the early stages will help to provide new diagnostic and therapeutic strategies and slow the transition from MCI to AD. Patients with AD may present with a concomitant metabolic disorder, such as diabetes, obesity, and dyslipidemia, as a risk factor for AD that may be involved in the onset of both AD pathology and cognitive impairment. Therefore, metabolite profiling, or metabolomics, can be very useful in diagnosing AD, developing new therapeutic targets, and evaluating both the course of treatment and the clinical course of the disease. In addition, studying the relationship between nutritional behavior and AD requires investigation of the role of conditions such as obesity, hypertension, dyslipidemia, and elevated glucose level. Based on this literature review, nutritional recommendations, including weight loss by reducing calorie and cholesterol intake and omega3 fatty acid supplementation can prevent cognitive decline and dementia in the elderly. The underlying metabolic causes of the pathology and cognitive decline caused by AD and MCI are not well understood. In this review article, metabolomics biomarkers for diagnosis of AD and MCI and metabolic risk factors for cognitive decline in AD were evaluated.
引用
收藏
页数:11
相关论文
共 122 条
[1]   Oleic Acid Ameliorates Amyloidosis in Cellular and Mouse Models of Alzheimer's Disease [J].
Amtul, Zareen ;
Westaway, David ;
Cechetto, David F. ;
Rozmahel, Richard F. .
BRAIN PATHOLOGY, 2011, 21 (03) :321-329
[2]   Dimethylarginines, Homocysteine Metabolism, and Cerebrospinal Fluid Markers for Alzheimer's Disease [J].
Arlt, Soenke ;
Schwedhelm, Edzard ;
Koelsch, Heike ;
Jahn, Holger ;
Linnebank, Michael ;
Smulders, Yvo ;
Jessen, Frank ;
Boeger, Rainer H. ;
Popp, Julius .
JOURNAL OF ALZHEIMERS DISEASE, 2012, 31 (04) :751-758
[3]   Metabolic Syndrome, Mild Cognitive Impairment, and Dementia: A Meta-Analysis of Longitudinal Studies [J].
Atti, Anna Rita ;
Valente, Stefano ;
Iodice, Antonia ;
Caramella, Ilaria ;
Ferrari, Barbara ;
Albert, Umberto ;
Mandelli, Laura ;
De Ronchi, Diana .
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2019, 27 (06) :625-637
[4]   Genome-wide Association Analysis Reveals Putative Alzheimer's Disease Susceptibility Loci in Addition to APOE [J].
Bertram, Lars ;
Lange, Christoph ;
Mullin, Kristina ;
Parkinson, Michele ;
Hsiao, Monica ;
Hogan, Meghan F. ;
Schjeide, Brit M. M. ;
Hooli, Basavaraj ;
DiVito, Jason ;
Ionita, Luliana ;
Jiang, Hongyu ;
Laird, Nan ;
Moscarillo, Thomas ;
Ohlsen, Kari L. ;
Elliott, Kathryn ;
Wang, Xin ;
Hu-Lince, Diane ;
Ryder, Marie ;
Murphy, Amy ;
Wagner, Steven L. ;
Blacker, Deborah ;
Becker, K. David ;
Tanzi, Rudolph E. .
AMERICAN JOURNAL OF HUMAN GENETICS, 2008, 83 (05) :623-632
[5]   Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis [J].
Bosco, Domenico ;
Fava, Antonietta ;
Plastino, Massimiliano ;
Montalcini, Tiziana ;
Pujia, Arturo .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2011, 15 (09) :1807-1821
[6]   Metabolic Dysfunction in Alzheimer's Disease and Related Neurodegenerative Disorders [J].
Cai, Huan ;
Cong, Wei-na ;
Ji, Sunggoan ;
Rothman, Sarah ;
Maudsley, Stuart ;
Martin, Bronwen .
CURRENT ALZHEIMER RESEARCH, 2012, 9 (01) :5-17
[7]   Metabolic Syndrome as a Risk Factor for Alzheimer's Disease: Is Aβ a Crucial Factor in Both Pathologies? [J].
Campos-Pena, Victoria ;
Toral-Rios, Danira ;
Becerril-Perez, Fernando ;
Sanchez-Torres, Carmen ;
Delgado-Namorado, Yair ;
Torres-Ossorio, Elimar ;
Franco-Bocanegra, Diana ;
Carvajal, Karla .
ANTIOXIDANTS & REDOX SIGNALING, 2017, 26 (10) :542-+
[8]   Searching for Disease-Modifying Drugs in AD: Can We Combine Neuropsychological Tools with Biological Markers? [J].
Caraci, Filippo ;
Castellano, Sabrina ;
Salomone, Salvatore ;
Drago, Filippo ;
Bosco, Paolo ;
Di Nuovo, Santo .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2014, 13 (01) :173-186
[9]   Metabolic Risk Factors of Sporadic Alzheimer's Disease: Implications in the Pathology, Pathogenesis and Treatment [J].
Chakrabarti, Sasanka ;
Khemka, Vineet Kumar ;
Banerjee, Anindita ;
Chatterjee, Gargi ;
Ganguly, Anirban ;
Biswas, Atanu .
AGING AND DISEASE, 2015, 6 (04) :282-299
[10]   Metabolic Dysfunction in Alzheimer's Disease: From Basic Neurobiology to Clinical Approaches [J].
Clarke, Julia R. ;
Ribeiro, Felipe C. ;
Frozza, Rudimar L. ;
De Felice, Fernanda G. ;
Lourenco, Mychael V. .
JOURNAL OF ALZHEIMERS DISEASE, 2018, 64 :S405-S426